This study investigates the combination of several treatments for patients with stage IV non-squamous non-small cell lung cancer (NSCLC). The purpose is to understand how well these treatments work together to stop the cancer from growing or spreading. NSCLC is a type of lung cancer that does not include squamous cells, and the study is for patients who have not received chemotherapy or immunotherapy before.

Participants in this study will receive a combination of medications through an intravenous (i.v.) line. These include carboplatin, pemetrexed, atezolizumab, and bevacizumab, given every three weeks for up to four cycles. If the cancer does not progress after these cycles, patients may continue with a maintenance therapy that includes pemetrexed, atezolizumab, and bevacizumab until the cancer progresses or side effects become too severe.

• Who can participate: Adults with non-squamous non-small cell lung cancer (NSCLC) confirmed by tests can join. Patients must not have received chemotherapy or immunotherapy before and can have had disease progression more than a year after prior adjuvant therapy for earlier stages.
• Study details: Participants will be given a combination of investigational medications through an i.v. line every three weeks. If the cancer does not progress after four cycles, they may continue with maintenance therapy. A placebo, which is an inactive substance, is not used in this study.